REG - Medpal AI PLC - Update on ATM Facility

Medpal AIAnnouncement

16/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251216:nRSP6638La&default-theme=true

RNS Number : 6638L  Medpal AI PLC  16 December 2025

16 December 2025

MedPal AI plc

("MedPal AI" or the "Company")

Update on ATM Facility

 

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on health and wellness management, is pleased to
provide an update on its At-The-Market ("ATM") equity issuance facility that
it announced on 4 December 2025.

 

The Company has raised gross proceeds of approximately £498,225 via the ATM
facility through the issue of 7,500,000  new ordinary shares  ("ATM Shares")
at an average price of 6.643p per  ATM Share. The proceeds of the ATM
facility will provide additional working capital for MedPal AI's recently
established online pharmaceutical subsidiary, MedPal Limited, to hold greater
levels of stock, expand product lines and to undertake marketing campaigns to
grow the pharmacy and clinic parts of the business, MedPal Pharmacy and
Medpal.clinic.

 

The announcement of 4 December 2025 can be viewed here
irtools.co.uk/90/story/3ba161d5-8560-4c6d-8de9-a40e8eb9f1c1
(https://irtools.co.uk/90/story/3ba161d5-8560-4c6d-8de9-a40e8eb9f1c1)

 

Admission and Voting Rights

 

Application has been made for the 7,500,000 ATM Shares to be admitted to
trading on AIM ("Admission"). Admission is expected to become effective and
dealings in the ATM Shares are expected to commence on or around 19 December
2025.

 

Upon Admission, the Company's issued ordinary share capital will consist of
427,399,640 Ordinary Shares with one voting right each. The Company does not
hold any Ordinary Shares in treasury. Therefore, from Admission the total
number of Ordinary Shares and voting rights in the Company will be
427,399,640. With effect from Admission, this figure may be used by
Shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts/ Nick Josh

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRFELLFELLEFBV



            Copyright 2019 Regulatory News Service, all rights reserved